A large-scale UK study has revealed a concerning link between the commonly prescribed antipsychotic drug risperidone and an increased risk of stroke in individuals with dementia. The findings, published in the British Journal of Psychiatry, challenge previous assumptions about patient risk and suggest that all dementia patients taking risperidone may be vulnerable, regardless of prior cardiovascular health. This research, involving over 165,000 patients, underscores the complex decisions clinicians and families face when managing severe agitation in dementia.
Risperidone is often used as a last resort to manage severe agitation and aggressive behaviors in dementia patients, particularly in care home settings where non-pharmacological approaches have proven insufficient. However, the latest study demonstrates a heightened stroke risk even in patients with no prior history of heart disease or stroke, prompting calls for a reevaluation of prescribing practices and monitoring protocols. Understanding the relationship between risperidone and stroke risk is crucial for informed patient care.
Stroke Risk Consistent Across Patient Groups
Researchers analyzed anonymized health records from the UK’s National Health Service (NHS) spanning from 2004 to 2023, comparing dementia patients prescribed risperidone with a control group not taking the medication. Dr. Byron Creese of Brunel University of London, a lead researcher on the project, explained that a key finding was the consistency of risk across different patient characteristics. “We knew Risperidone causes stroke, but we didn’t recognize whether some groups of people might be more at risk than others. We thought if we might identify characteristics that develop people more at risk, doctors could avoid prescribing to patients with those characteristics,” he stated.
The study found that among individuals with a prior stroke, the annual stroke rate per 1,000 person-years was 22.2 percent for those taking risperidone, compared to 17.7 percent for those not on the drug. Even among patients with no prior stroke history, a noticeable increase in risk was observed, with rates reaching 2.9 percent for risperidone users versus 2.2 percent in the control group. Notably, the research also indicated a higher stroke risk associated with shorter durations of risperidone use – within the first 12 weeks.
Balancing Benefits and Risks
Approximately half of all individuals living with dementia experience agitation, a symptom that can cause significant distress for both the patient and their caregivers. When behavioral interventions and other non-drug strategies fail, clinicians may turn to risperidone to manage these challenging symptoms. However, this decision requires careful consideration of the potential benefits against the increased risk of serious side effects, such as stroke.
Currently, the UK’s National Health Service (NHS) recommends limiting risperidone treatment to six weeks when used for severe symptoms. However, in practice, many patients continue the medication for longer periods, and monitoring practices can vary considerably across different regions. Adding to the complexity, You’ll see currently no licensed alternative drugs specifically approved for treating severe agitation in dementia patients in the UK, according to Dr. Creese. This lack of alternatives underscores the need for doctors to thoroughly explain the risks and benefits of risperidone to patients and their families.
As ScienceDaily reports, the findings highlight the absence of a clearly “safe” patient group when considering risperidone use.
Looking Ahead: Updated Guidance and Personalized Care
The researchers hope their findings will inform updated clinical guidance that prioritizes a more personalized approach to prescribing risperidone. “We hope that these data can be used in updated guidance that is more person centered and based on particular patient characteristics,” Dr. Creese said. The study emphasizes the importance of open and honest conversations between doctors, patients, and families to ensure informed decision-making.
This research adds to a growing body of evidence linking antipsychotic use to adverse outcomes in dementia patients. A previous study published in The BMJ found that antipsychotic use was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, and other serious health issues.
The findings underscore the need for continued research into alternative treatments for agitation in dementia and for improved monitoring strategies to mitigate the risks associated with risperidone use.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
What are your thoughts on these findings? Share your comments below, and please share this article with anyone who might find it helpful.
